Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45.

PubMed  Article  Google Scholar 

De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–35.

PubMed  Article  Google Scholar 

Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature. 1988;334(6180):345–8.

CAS  PubMed  Article  Google Scholar 

Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, Frank MJ, Jahanshahi M. Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727–40.

PubMed  Article  Google Scholar 

Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17(6):559–68.

PubMed  Article  Google Scholar 

Biundo R, Weis L, Antonini A. Cognitive decline in Parkinson’s disease: the complex picture. npj Parkinson’s Dis. 2016;2(1):1–7.

Google Scholar 

Ghadery C, Koshimori Y, Christopher L, Kim J, Rusjan P, Lang AE, Houle S, Strafella AP. The interaction between neuroinflammation and β-amyloid in cognitive decline in Parkinson’s disease. Mol Neurobiol. 2020;57(1):492–501.

CAS  PubMed  Article  Google Scholar 

Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(6):1454–76.

PubMed  PubMed Central  Article  Google Scholar 

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, Zhang J. Parkinson Study Group DATATOP Investigators CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(3):271–6.

PubMed  PubMed Central  Article  Google Scholar 

Price DL. New Perspectives on Alzheimer's Disease. Annu Rev Neurosci 1986;9(1):489–512. https://doi.org/10.1146/annurev.ne.09.030186.002421

Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85–91.

PubMed  PubMed Central  Article  Google Scholar 

Kim J, Ghadery C, Cho SS, Mihaescu A, Christopher L, Valli M, Houle S, Strafella AP. Network patterns of beta-amyloid deposition in Parkinson’s disease. Mol Neurobiol. 2019;56(11):7731–40.

CAS  PubMed  Article  Google Scholar 

Melzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Grenfell S, Horne KL, Young BN, Pascoe MJ. Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Front Neurol. 2019;10:391.

PubMed  PubMed Central  Article  Google Scholar 

Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ. ICICLE-PD study group. Cognitive decline and quality of life in incident Parkinson’s disease: the role of attention. Parkinsonism Relat Disord. 2016;27:47–53.

PubMed  PubMed Central  Article  Google Scholar 

Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Burn DJ. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):648–52.

PubMed  Article  Google Scholar 

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.

PubMed  Article  Google Scholar 

Broeders M, Velseboer DC, de Bie R, Speelman JD, Muslimovic D, Post B, de Haan R, Schmand B. Cognitive change in newly-diagnosed patients with Parkinson’s disease: a 5-year follow-up study. J Int Neuropsychol Soc. 2013;19(6):695–708.

PubMed  Article  Google Scholar 

Chung SJ, Park YH, Yoo HS, Lee YH, Ye BS, Sohn YH, Lee JM, Lee PH. Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease. Neurobiol Aging. 2019;78:168–77.

PubMed  Article  Google Scholar 

Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88(8):767–74.

PubMed  Article  Google Scholar 

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Widner H, Decraemer H, Nägga K, Minthon L. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–52.

PubMed  Article  Google Scholar 

Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14(9):626–36.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–61.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J. 2015;471(3):323–33.

CAS  PubMed  Article  Google Scholar 

Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019;51(5):1.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358–68.

Pearson HA, Peers C. Physiological roles for amyloid β peptides. J Physiol. 2006;575(1):5–10.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci. 2003;23(13):5531–5.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Morley JE, Farr SA, Nguyen AD, Xu F. what is the physiological function of amyloid-Beta protein? J Nutr Health Aging. 2019;23(3):225–6.

CAS  PubMed  Article  Google Scholar 

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ. Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE. 2017;12(5): e0177924.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.

PubMed  Article  Google Scholar 

LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269(38):23403–6.

CAS  PubMed  Article  Google Scholar 

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord Off J Mov Disord Soc. 2008;23(15):2129–70.

Article  Google Scholar 

Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1998;50(2):318.

PubMed  Article  Google Scholar 

Yesavage JA. Geriatric depression scale. Psychopharmacol Bull. 1988;24(4):709–11.

CAS  PubMed  Google Scholar 

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.

Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008;23(7):1043–6.

Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717–25.

CAS  PubMed  Article  Google Scholar 

Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–45.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Fiorenzato E, Biundo R, Cecchin D, Frigo AC, Kim J, Weis L, Strafella AP, Antonini A. Brain amyloid contribution to cognitive dysfunction in early-stage Parkinson’s disease: the PPMI dataset. J Alzheimers Dis. 2018;66(1):229–37.

CAS  PubMed  Article  Google Scholar 

Ward JH Jr. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58(301):236–44.

Article  Google Scholar 

Inguanzo A, Sala-Llonch R, Segura B, Erostarbe H, Abós A, Campabadal A, Uribe C, Baggio HC, Compta Y, Marti MJ, Valldeoriola F. Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease. Parkinsonism Relat Disord. 2021;82:16–23.

CAS  PubMed  Article